5-[(3-chloro-4-fluorobenzene)sulfonamidomethyl]-N-[(2-methyl-1,3-thiazol-5-yl)methyl]pyrazine-2-carboxamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 5-[(3-chloro-4-fluorobenzene)sulfonamidomethyl]-N-[(2-methyl-1,3-thiazol-5-yl)methyl]pyrazine-2-carboxamide
• 英文别名: 5-(((3-chloro-4-fluorophenyl)sulfonamido)methyl)-N-((2-methylthiazol-5-yl)methyl)pyrazine-2-carboxamide；5-({[(3-Chloro-4-Fluorophenyl)sulfonyl]amino}methyl)-N-[(2-Methyl-1,3-Thiazol-5-Yl)methyl]pyrazine-2-Carboxamide；5-[[(3-chloro-4-fluorophenyl)sulfonylamino]methyl]-N-[(2-methyl-1,3-thiazol-5-yl)methyl]pyrazine-2-carboxamide
• 化学式: C₁₇H₁₅ClFN₅O₃S₂
• 分子量: 455.921
• InChiKey: BRNKHERDLJYUNK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  29
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  151
• 氢给体数：
  2
• 氢受体数：
  9

文献信息

• N-ARYLMETHYL SULFONAMIDE NEGATIVE MODULATORS OF NR2A
  申请人：Mnemosyne Pharmaceuticals, Inc.

  公开号：US20150141433A1

  公开（公告）日：2015-05-21

  Compounds that selectively negatively modulate NMDA receptors containing an NR2A subunit, pharmaceutical compositions comprising the compounds, and methods of treating a disease using the compounds are disclosed.

  本发明公开了选择性负调节含有NR2A亚基的NMDA受体的化合物、包含该化合物的制药组合物以及使用该化合物治疗疾病的方法。
• COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY
  申请人：Poddar Ranjana

  公开号：US20210252026A1

  公开（公告）日：2021-08-19

  A method for treating a hyperhomocysteinemic subject having cerebral ischemic stroke generally includes administering to the hyperhomocysteinemic subject, following cerebral stroke, a composition that includes an inhibitor or an antagonist of a GluN2A-containing N-methyl-D-aspartate receptor (NMDAR) in an amount effective to ameliorate at least one symptom or clinical sign of cerebral stroke.
• US9963434B2
  申请人：——

  公开号：US9963434B2

  公开（公告）日：2018-05-08
• [EN] N-ARYLMETHYL SULFONAMIDE NEGATIVE MODULATORS OF NR2A<br/>[FR] MODULATEURS NÉGATIFS N-ARYLMÉTHYL SULFONAMIDE DE NR2A
  申请人：MNEMOSYNE PHARMACEUTICALS INC

  公开号：WO2015048503A2

  公开（公告）日：2015-04-02

  Compounds that selectively negatively modulate NMDA receptors containing an NR2A subunit, pharmaceutical compositions comprising the compounds, and methods of treating a disease using the compounds are disclosed.